Abstract
The article presents data on the effectiveness the drug fructose-1,6-diphosphate in patients with chronic forms of coronary heart disease. Drugs of this class provide reduction of oxygen demand of ischemic myocardium by optimizing energy exchange at a certain residual level of blood supply (including in the peri-infarction zone) by reducing fatty acid oxidation in mitochondria and stimulating glycolysis, requiring 13% fewer oxygen molecules. This preserves myocardial viability in the ischaemic zone. The results of the study showed that the inclusion of the drug fructose-1,6-diphosphate in the complex therapy of coronary heart disease makes it possible to accelerate the dynamics of ECG, has anti-inflammatory, antiarrhythmic, antianginal and anti-ischemic effect, thereby improving the quality of life of patients with chronic forms of coronary heart disease.
References
Amosova E.N. Metabolic therapy of myocardial damage caused by ischemia: a new approach to the treatment of coronary heart disease and heart failure // Ukr. cardiol. magazine - 2000. - No. 4. - P. 86–9.
Belardinelli R. Beneficial effects of the metabolic approach in the rehabilitation of patients with heart disease // Heart and metabolism. Efficiency of cardiac activity in normal conditions and in diseases. - 2009. - No. 23. - P. 21–24.
Belousov Yu.B., Namsaraev Zh.N. (2004) Endothelial dysfunction as a cause of atherosclerotic arterial lesions in arterial hypertension: methods of correction. Farmateka, 6(84): 62–72.
Vizir V.A., Berezin A.E. (2000) The role of endothelial dysfunction in the formation and progression of arterial hypertension. Prognostic value and prospects for treatment. Ukr. med.chasopis, 4(18): 23–33 23–33 (http://www.umj.com.ua/rus/article/2097; http://www.umj.com.ua/archive/18/pdf/1056_rus.pdf).
Golovchenko Yu.I., Treschinskaya M.A. (2008) Review of current understanding of endothelial dysfunction. Consilium medicum Ukraina, 11:38–40.
Gurevich M.A., Sturov N.V. (2006) Nitric oxide deficiency and maintenance of vascular homeostasis: the role of mononitrates and problems of cytoprotection. The Difficult Patient, 3:23–29.
Elsky V.N., Vatutin N.T., Kalinkina N.V., Salakhova A.M. (2008) The role of endothelial dysfunction in the genesis of cardiovascular diseases. Journal. AMS of Ukraine, 14(1): 51–62.
Malakhov V.A., Zavgorodnyaya A.N. (2007) The nitric oxide system in cerebral ischemic stroke: some pathogenetic aspects. Ukr. med.chasopis, 2(58): 97–100
Markov Kh.M. (2000) The role of nitric oxide in the pathogenesis of childhood diseases. Ros. vestn. perinatol. and Pediatrician, 4:43–47.
Movchan E.A. (2008) Endothelial and platelet dysfunction in chronic kidney disease: a new look at the old problem of disorders in the hemostasis system in patients with glomerulonephritis. Bulletin of Siberian Medicine, Appendix 2: 88–96.
Slobodsky V.A. (2009) Evaluation of the use of Tivortin® aspartate in treating patients with stable angina pectoris. Ukr. med.chasopis, 5(73): 40–43
Sozykin A.V., Noeva E.A., Balakhonova T.V. et al. (2000) Effect of L-arginine on platelet aggregation, endothelial function, and exercise tolerance in patients with stable exertional angina. Ter. a archive, 72(8): 24–27.
Stepanov Yu.M., Kononov I.N., Zhurbina A.I., Filippova A.Yu. (2004) Arginine in medical practice. Journal. AMS of Ukraine, 10(1): 340–352.
Baylis C. (2008) Nitric oxide deficiency in chronic kidney disease. Am. J. Physiol. Renal Physiol., 294: 1–9.
Bednarz B., Jaxa-Chamiec T., Gebalska J. et al. (2004) L-arginine supplementation prolongs exercise capacity in congestive heart failure. Kardiol. Pol., 60(4): 348–353.
Bednarz B., Jaxa-Chamiec T., Maciejewski P. et al. (2005) Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol. Pol., 62(5): 421–427.
Bocchi E.A., Vilella de Moraes A.V., Esteves-Filho A. et al. (2000) L-arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin. Cardiol., 23(3): 205–210.
Bode-Böger S.M., Muke J., Surdacki A. et al. (2003) Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc. Med., 8(2): 77–81.
Böger R.H. (2007) The pharmacodynamics of L-arginine. J. Nutr., 137: 1650S–1655S.
Bryan N.S., Bian K., Murad F. (2009) Discovery of the nitric oxide signaling pathway and targets for drug development. Frontiers in Bioscience, 14: 1–18.
Buhimschi I.A., Saade G.R., Chwalisz K., Garfield R.E. (1998) The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Human Reproduction Update, 4(1): 25–42.
Chatterjee A., Catravas J.D. (2008) Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul. Pharmacol., 49(4–6): 134–140.
Facchinetti F., Saade G.R., Neri I. et al. (2007) L-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens Pregnancy, 26(1): 121–130.
George J., Shmuel S.B., Roth A. et al. (2004) L-arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty. Atherosclerosis, 174(2): 323–327.
Cargnoni A., Pasini E., Ceconi C. et al. Insight into cytoprotection with metabolic agents // Eur. Heart J. (Suppl.) 1999. Vol. 1. P. 40–48.
Stanley W.C. et al. Metabolic therapy in the treatment of ischemic heart disease: the pharmacology of trimetazidine // Fundam. Clin. Pharmacol. 2003. Vol. 17. P.133–145.